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Memory enhancementQuercetin is a well-known flavonoid, has low bioavailability. Quercetin nanoparticles (NQC) enhance its
bioavailability. NQC were not explored for their potential therapeutic activities in Alzheimer’s disease
(AD). Hence, the present study was performed to evaluate the protective effect of NQC in comparison
to free quercetin against scopolamine induced spatial memory impairments.
NQC prepared by anti solvent precipitation method. Quercetin, NQC (30 mg/kg p.o.) and rivastigmine
(2 mg/kg i.p.) as a reference drug were administered for 8 consecutive days. At the end of the treatment
period memory impairments were induced by a single injection of scopolamine (20 mg/kg; i.p.).
Conditioned avoidance and rectangular-maze tests were conducted 30 min thereafter then rats were sac-
rificed and brain homogenates were used for the estimation of glutathione (GSH), catalase and malondi-
aldehyde (MDA) contents together with acetyl cholinesterase (AchE) activity. In addition, histopathologic
studies were also performed.
The size of NQC was observed below 300 nm. NQC significantly reduced the transfer latency and con-
ditioned avoidance response compared to scopolamine treated group (p < 0.05). Pretreatment with NQC
showed a significant (p < 0.05) decrease in MDA, AchE levels and increase in brain catalase and GSH levels
to be similar to that observed in the rivastigmine group.
In all the behavioral, biochemical and histological experiments, the rats treated with NQC showed addi-
tional distinguished results compared to quercetin group indicating that a preventive strategy against the
progression of AD. This approach of quercetin nanoparticles provides the potential therapeutic applica-
tion in human neurodegenerative disease in future.
 2016 Publishing services provided by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Alzheimer’s disease (AD) is a chronic neurodegenerative disor-
der with the progressive decline in memory [1]. AD is character-
ized by cerebral oxidative stress accompanied by loss of
cholinergic neurons in the basal forebrain and hippocampus
[2,3]. Central cholinergic neuronal activity plays an important role
in learning and memory [4]. Multiple neurotransmitters and neu-
ronal pathways are involved in the process of memory formation
[5]. Functional deficits in the cholinergic system are associated
with cognitive impairments observed in AD [6].
Scopolamine a muscarinic cholinergic receptor antagonist has
profound amnesic effects in experimental animals. Scopolamine
induced amnesia has been widely adopted the experimentalanimal model to screen for drugs with potential therapeutic values
in dementia [7] it interferes with acetylcholine transmission in the
central nervous system, leading to cholinergic dysfunction and
memory impairments in rats [8,9].
Acetyl cholinesterase inhibitors, such as rivastigmine,
galantamine and donepezil, are the most effective and approved
pharmacotherapeutic agents for cognitive dysfunction [10].
Rivastigmine is a pseudo irreversible inhibitor of both acetyl-
cholinesterase and butyrylcholinesterase [9]. Despite intensive
advancement in research, available drugs are not ideal for clinical
use due to their undesirable side effects [11,12] thus, it is necessary
to search for alternative or adjuvant anti amnestic therapies.
Today, it is best known that medicinal plants attracted attention
due to their use in the treatment of cognitive disorders [13].
Quercetin is a well-known flavonoid in the human diet, present
in vegetables, herbs, edible fruits and other related products eg.
Red wine [14], Ginko Biloba [15] and onions [16]. Quercetin is
one of the prominent dietary antioxidants it shows biologicallogical
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inflammation [18] and cardiovascular diseases [19]. Despite these
medicinal benefits, quercetin has low bioavailability (less than
17% in rats and even 1% in human) [20,21] due to its poor aqueous
solubility, as a result, the clinical application of this drug greatly
restricted. Therefore, it becomes necessary to develop a system
which could increase the solubility of quercetin.
Nanoparticles are particularly suitable for drug delivery for
water insoluble compounds such as quercetin. According to
Noyes-Whitney equation [22] a decrease in particle size will lead
to an increase in effective surface area which results in enhanced
bioavailability. In the present study, quercetin nanoparticles
(NQC) prepared by anti solvent precipitation method using syringe
pump to enhance its bioavailability in therapeutic application. The
aim of our present study was to evaluate the protective effect of
NQC in comparison to free quercetin against scopolamine induced
spatial memory impairments.2. Materials and methods
2.1. Materials
Rivastigmine used as a reference drug obtained from Vasudha
Pharma Chemicals Ltd, Hyderabad, India. Scopolamine hydrobro-
mide used as a dementia inducing agent obtained from Boehringer
Ingelheim, Quercetin, 5,5-dithio-bis2-nitro benzoic acid, (Ellman’s
reagent), acetylthiocholine iodide, were purchased from Sigma–
Aldrich (USA), the absolute ethanol (99.5–99.8%) was obtained
from Merck, Mumbai, India. All other reagents used were also of
analytical grade.2.2. Preparation of NQC [23]
Quercetin was dissolved in the solvent (ethanol) at a concentra-
tion of 5 mg/ml. The syringe was filled with the prepared solution
and secured onto a syringe pump. The drug solution was quickly
injected at a fixed flow rate (8 ml/min) into the anti-solvent
(deionized water) of definite volume under magnetic stirring
(1000 rpm). Ethanol to water volume ratios used was 1:25. The
quercetin nanoparticles were filtered and vacuum dried.2.3. Particle morphology
The particle size and morphology of samples was observed
using a Scanning Electron Microscope (SEM) Zeiss EVO 18-EDX
special edition machine compatible with EDX machine. The pow-
der samples were spread on a SEM stub and sputtered with gold
before the SEM observations. The particle size and texture of
nanoparticles can be analyzed by using image magnification soft-
ware compatible with SEM and helps in determining the presence
and formation of NQC. Five SEM pictures were used to find the
average range of particle diameter.2.4. Animals
The study was performed on male Albino Wistar rats (150–
250 g). All animals were procured from Mahaveera enterprises,
Hyderabad. The animals were maintained under a controlled
12 h light/dark cycle. Handling and experimentation were con-
ducted in accordance with the approved guidelines of the Commit-
tee for the Purpose of Control and Supervision of Experiments on
Animals (CPCSEA), New Delhi and the experimental protocol was
approved by Institutional Animal Ethical Committee (IAEC),
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In both behavioral tasks such as conditioned avoidance test and
rectangular maze, rats were randomly allocated into five groups (6
rats each) as follows: group I received saline and served as control
while group II received scopolamine (20 mg/kg, i.p.). Groups III–V
received rivastigmine (2 mg/kg, i.p.), Quercetin (30 mg/kg, p.o.),
NQC (30 mg/kg, p.o.). The animals were trained for 7 days. During
which they do not receive any drug. The completely trained ani-
mals were chosen for the study. These animals were dosed once
in a day with the respective drugs for 8 days along with daily train-
ing trial. Scopolamine was administered as a single dose 30 min
after the last administration in groups II–V.
2.6. Behavioral experiments
2.6.1. Conditioned avoidance test
The test was carried out using a shuttle box as described by Hin-
richs et al. [24]. In this experiment, the rat is placed in a two-
compartment shuttle box and presented with a conditioned stim-
ulus such as a light, followed after a short delay by an aversive
unconditioned stimulus foot-shock. After injection of scopolamine,
each rat was placed in the shuttle box and allowed to adapt for
3 min. Following adaptation, the conditioned stimulus was pre-
sented for 20 s prior to the unconditioned stimulus. If the rat
crossed to the next compartment during 20 s of conditioned stim-
ulus the electric shock was avoided otherwise, failure of avoidance
was recorded.
2.6.2. Rectangular maze test
Rectangular maze is used for studying learning, memory in ani-
mals. The maze consists of completely enclosed rectangular box
divided into chamber A, in which the rat is placed and has a sliding
door that is opened to allow the rat to enter the maze; chamber C.
The maze, animal has to explore and reward chamber B, at the
other end of maze in which the reward is kept. Well-trained ani-
mals were taken for the experiment. Transfer latency (Time taken
in seconds by the animal to reach reward chamber from chamber
A) was recorded. For each animal, four readings were taken and
the average is taken as learning score (transfer latency) for that
animal. Lower scores of the assessment indicate efficient learning
while higher scores indicate poor learning in animals [25].
2.7. Brain homogenate preparation
Immediately after performing the behavioral tests, rats were
sacrificed by decapitation. The brains were removed; a (10% w/v)
homogenate was prepared in ice-cold 50 mM phosphate buffer
(pH 7.4). The homogenate was centrifuged at 10,000 rpm for
15 min and aliquots of supernatant were separated and used for
biochemical estimation.
2.8. Histopathologic examination of brain tissues
The histopathologic assessment was performed on the brains of
different groups. Brains were removed from the skull and post-
fixed overnight in paraformaldehyde. Coronal sections of 5 lm
thickness were cut using microtome and the sections were stained
with hematoxylin and eosin and examined microscopically.
2.9. Determination of biochemical markers in brain homogenate
The method for the assessment of MDA content in the brain
homogenates was based on that of Ruiz-Larrea et al. [26] the
supernatant was read spectrophotometrically at 532 nm and
MDA brain content was expressed as nmol/mg tissue. GSH levelattenuates scopolamine induced spatial memory deficits and pathological
/10.1016/j.bfopcu.2016.10.004
Fig. 2. Effect of NQC on avoidance response in conditioned avoidance test against
scopolamine induced amnesia. Each bar with vertical line represents the mean of 6
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method as described by Ellman and Bulaj et al. [27,28]. The optical
density of the produced colored product was determined at
412 nm using the spectrophotometer. Calculation of GSH content
was based on a standard glutathione curve and expressed as
lmol/mg tissue. Catalase activity was estimated by the method
of Beer and Seizer [29] based on the ability of catalase to oxidize
hydrogen peroxide. The change in absorbance was recorded at
240 nm using the spectrophotometer. The results were expressed
as nano moles of H2O2 decomposed per minute per mg protein. Ell-
man method [27] was used to estimate brain AChE activity. AChE
activity was determined spectrophotometrically at 412 nm. The
activity of AchE was expressed in lmole/min/mg of protein.rats ± S.E.M. Statistical analysis was carried out using One-Way ANOVA followed by
Bonferroni multiple comparisons test; #p < 0.05 vs. control, *p < 0.05 vs.
scopolamine.2.10. Statistical analysis
The mean ± SEM, were calculated for all data. Significant differ-
ence between means was evaluated by one-way analysis of vari-
ance (ANOVA) followed by Bonferroni multiple comparison tests.
P < 0.05 was considered as statistically significant.3. Results
3.1. NQC characterization by SEM
SEM micrographs of the quercetin and NQC are shown in
Fig. 1a and b. It is observed that the quercetin powder (Fig. 1a)
exhibited particles lacking uniformity in size and were much larger
than the NQC (Fig. 1b). On the other hand, NQC prepared by syringe
pump exhibited particles uniformity in size, less crystallinity, and
absence of larger particles (Fig. 1b). As depicted in the image, the
particles possessed uniform shape. The size of all particles was
found to be less than 300 nm.3.2. Effect of NQC on scopolamine-induced memory impairment in the
conditioned avoidance test
Administration of scopolamine (20 mg/kg) as a single i.p. injec-
tion resulted in a significant increase in conditioned avoidance
response (p < 0.05) as compared to the control group. Pretreatment
with rivastigmine or quercetin or NQC significantly reduced the
conditioned avoidance response compared to scopolamine treated
group (p < 0.05) and control group (p < 0.05), respectively (Fig. 2).Fig. 1. SEM photographs of a
Please cite this article in press as: S. Palle, P. Neerati, Quercetin nanoparticles
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rectangular maze test
Scopolamine-induced dementia significantly increased the
transfer latency (p < 0.05) as compared to the normal group. How-
ever, Pretreatment with rivastigmine or quercetin or NQC signifi-
cantly reduced the transfer latency compared to scopolamine
treated group (p < 0.05) and control group (p < 0.05), respectively
(Fig. 3).
3.4. Effect of NQC on lipid peroxidation
Table 1 depicts effect of different treatments on LPO, which
measured as MDA levels in brain homogenate. The MDA content
expressed as nmol/mg tissue was significantly higher in
scopolamine-treated rats (3.579 ± 0.1762) as compared to the con-
trol group (0.6853 ± 0.2096). Pre treatment with NQC significantly
reduced MDA levels (p < 0.05) when compared scopolamine group
and restored MDA brain levels to be similar to rivastigmine group
(1.151 ± 0.1703). Quercetin did not show the significant reduction
in MDA levels (2.927 ± 0.1245) when compared scopolamine
group.
3.5. Effect of NQC on GSH activity
Animals subjected to scopolamine treatment showed a signifi-
cant reduction in GSH (1.167 ± 0.3380) levels as compared to con-
trol group (4.933 ± 0.4723). NQC pretreatment showed a
significant increase in brain GSH levels (p < 0.05) when compared
to scopolamine group. NQC increased brain GSH levels to a similar
level as the rivastigmine group. Quercetin did not show the) Quercetin and b) NQC.
attenuates scopolamine induced spatial memory deficits and pathological
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Fig. 3. Effect of NQC on latency time in rectangular maze test against scopolamine
induced amnesia. Each bar with vertical line represents the mean of 6 rats ± S.E.M.
Statistical analysis was carried out using One-Way ANOVA followed by Bonferroni
multiple comparisons test; #p < 0.05 vs. control, *p < 0.05 vs. scopolamine.
Table 1
Effect of NQC on scopolamine induced oxidative stress parameters in rat brain.






I Control 0.6853 ± 0.2096* 4.933 ± 0.4723* 5.124 ± 0.3174*
II Scopolamine 3.579 ± 0.1762# 1.167 ± 0.3380# 1.574 ± 0.1736#
III Rivastigmine 1.151 ± 0.1703* 4.402 ± 0.7910* 4.581 ± 0.1834*
IV Quercetin 2.927 ± 0.1245 2.960 ± 0.2749 2.340 ± 0.1120
V NQC 1.988 ± 0.2214* 4.378 ± 0.5163* 3.682 ± 0.2676*
The results expressed as mean ± SEM, n = 6. Statistical analysis was carried out by
One-way ANOVA followed by Bonferroni multiple comparison test.
* p < 0.05 versus scopolamine group.
# p < 0.05 versus control group.
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scopolamine group (Table 1).
3.6. Effect of NQC on catalase activity
Catalase levels were significantly reduced in scopolamine-
treated groups (1.574 ± 0.1736) compared to the control group
(5.124 ± 0.3174). NQC pretreatment showed a significant increase
in brain catalase levels (p < 0.05) when compared to scopolamine
group. Quercetin did not show the significant increase in catalase
levels (2.340 ± 0.1120) when compared scopolamine group
(Table 1).
3.7. Brain cholinesterase activity
Scopolamine administration significantly increased the brain
AchE activity (p < 0.05) as compared to the control group. Rivastig-
mine or NQC treatment significantly reduced the (p < 0.05)
scopolamine-induced elevation in AchE activity as compared to
scopolamine control group. Quercetin did not show the significant
reduction in brain AchE activity when compared scopolamine
group (Table 2).Table 2
Effect of NQC on brain cholinesterase activity of scopolamine-treated rats.
Treatment groups AchE activity (lmol/min/mg pr)
I Control 0.03261 ± 0.001123*
II Scopolamine 0.06585 ± 0.001683#
III Rivastigmine 0.0416 ± 0.003533*
IV Quercetin 0.05722 ± 0.003927
V NQC 0.04946 ± 0.0008207*
The results expressed as mean ± SEM, n = 6. Statistical analysis was carried out by
One-way ANOVA followed by Bonferroni multiple comparison test.
* p < 0.05 versus scopolamine group.
# p < 0.05 versus control group.
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Histological examination of hematoxylin and eosin stained
brain sections revealed serious damaging effects of scopolamine
on brain tissues compared to normal brain sections. A total number
of degenerating neurons with pyknotic and condensed nuclear
morphology were evaluated. Here, the data presented are the aver-
age of ten fields/section and shown in the graph. A. In the control
group, normal architecture of brain observed. B. In scopolamine
administered group abnormal cellular morphology with changes
like gliosis were observed. C. Normal architecture similar to the
control group was observed in rivastigmine pretreated group. D.
Protected cellular morphology was observed in quercetin treated
group. E. Morphological abnormalities were significantly reduced
in NQC group (Fig. 4).4. Discussion
In the field of medical science and drug delivery nanotechnol-
ogy has opened several new possibilities which improve site-
specific action of drugs [30,31]. Nanoparticles have increasingly
been used for a variety of neurological disorders [32]. Many
approaches have been developed to enhance the bioavailability
of poorly water soluble compounds including particle size reduc-
tion or generation of amorphous particle state and also the physi-
cal modification of drug which increases the surface area and
solubility of the drug particles [33,34]. Nanoparticles in the size
of approximately 10–1000 nm have a higher potential to circulate
in the blood for a longer period of time and also have the advantage
of high biocompatibility and increased bioavailability [35].
In the present study, the particle size of quercetin made smaller
and uniform by antisolvent precipitation method. The size range of
NQC was observed below 300 nm using scanning electron micro-
scope which makes the delivery system very much suitable for
the drug delivery to target organs.
Previous studies revealed that Quercetin has antioxidant activ-
ity [36,37], but to our knowledge NQC were not explored for their
potential therapeutic activities against scopolamine- induced spa-
tial memory impairments. Scopolamine, a nonselective muscarinic
antagonist produces memory deficits that are similar to those
found in age related senile central nervous system dysfunction
[5]. It became a widely used standard drug for inducing cognitive
deficits in animal model besides its use as a treatment for central
nervous system dysfunction such as motion sickness and opioid
addiction [38].
In the present experiments, i.e. rectangular maze test and con-
ditioned avoidance test, it is clearly seen that there was an increase
in the transfer latency in scopolamine treated group, which
demonstrates memory impairment. Quercetin and NQC adminis-
tration to scopolamine received animals reversed the increase in
latency time. NQC treated group has shown the more protective
effect against scopolamine-induced memory loss when compared
to quercetin treated group, which indicates improved therapeutic
efficacy of NQC.
Cholinergic neurotransmission plays an important role in learn-
ing and memory process [39,40], acetylcholinesterase is the
enzyme responsible for termination of cholinergic transmission
by hydrolysis of acetylcholine [41]. Therefore, acetylcholinesterase
inhibitory activity allows more amount of acetylcholine to retain in
the brain which enhances cognitive function. The cholinergic
hypothesis and evidence of the involvement of this system in the
etiology of AD play an important role in the identification of novel
cholinergic interventions as treatment for this disease.
Flavonoids have also reported to act as acetylcholinesterase
inhibitors [42]. Interestingly, NQC group has shown the moreattenuates scopolamine induced spatial memory deficits and pathological
/10.1016/j.bfopcu.2016.10.004
Fig. 4. Representative photomicrographs of Hematoxylin and Eosin (H&E) stained rat brains from each studied group. These Figures (A), (B), (C), (D), (E) are control,
scopolamine, rivastigmine, quercetin and NQC, respectively, representing the histological sections of the brain tissue showing damaging effects of scopolamine and protective
cellular morphology against scopolamine.
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compared to quercetin group.
Several studies have shown that oxidative stress is associated
with the pathophysiology of many neurological disorders and
brain dysfunction [43]. Therefore, neuronal cell death by oxidative
stress and progression of neurodegenerative disorders can be
attenuated by the supplementation of antioxidants and free radical
scavengers [44]. Administration of scopolamine is associated with
increased brain lipid peroxides and reduced brain antioxidant
levels [45]. GSH is an essential tri peptide, an antioxidant found
in all animal cells. It protects cells from singlet oxygen, superoxide
radical and hydroxyl radical damage. MDA is an end product of
lipid peroxidation, a measure of free radical generation [10].
In the present study, Scopolamine administration resulted in
increased brain lipid peroxidation parallel to reduced catalase
and GSH activities. Pretreatment with NQC showed a significant
decrease in MDA and increase in brain catalase and GSH contents
to be similar to that observed in the rivastigmine group when com-
pared to quercetin group.
Recently, many studies reported that antioxidation is one
mechanism of action of the flavonoids, these antioxidant abilitiesPlease cite this article in press as: S. Palle, P. Neerati, Quercetin nanoparticles
damages in rats, Bulletin Facult Pharmacy Cairo Univ (2016), http://dx.doi.orgresults in effective protection of neurons against neurotoxins, sup-
pression of neuronal inflammation and enhanced neuronal func-
tion [46,47]. Previous findings suggest that quercetin perhaps
possess memory enhancing ability through modulation of signal
cascades, in addition to its antioxidant properties [48].5. Conclusion
In conclusion, the formulated nanoparticles exhibited nanome-
ter range in size. According to our results, scopolamine-induced
behavioral, biochemical and histological changes were attenuated
by pretreatment of rats with NQC indicating that a preventive
strategy against the progression of AD. In all the experimental
models NQC has shown more prominent results compared to
quercetin group suggesting that increased efficacy is due to pro-
longed residence time in systemic circulation and increased
bioavailability. This approach of delivering a nontoxic herb origin
antioxidant, quercetin in the form of nanoparticles offers the
potential clinical application in human neurodegenerative disease
in future.attenuates scopolamine induced spatial memory deficits and pathological
/10.1016/j.bfopcu.2016.10.004
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